

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Gender Male

Diagnoses

Patient must have **ONE** of the following:

1. Castration-resistant prostate cancer (CRPC)
 - a. Patient is receiving gonadotropin-releasing hormone (GnRH) analog **OR** patient has had a bilateral orchiectomy
2. Metastatic castration-sensitive prostate cancer (mCSPC)
 - a. Patient is receiving gonadotropin-releasing hormone (GnRH) analog **OR** patient has had a bilateral orchiectomy
3. Non-metastatic castration-sensitive prostate cancer (nmCSPC)
 - a. Biochemical recurrence at high risk for metastasis (high-risk BCR)

AND ALL of the following for **ALL** indications:

1. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)
2. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Xtandi and for 3 months after the last dose

Prior - Approval Limits

Quantity

Strength	Quantity
40 mg	160 mg per day
80 mg	

Duration 12 months

Prior – Approval *Renewal* Requirements

Same as above

Prior - Approval *Renewal* Limits

Same as above

Appendix 1 - List of Androgen Receptor Inhibitors

Generic Name	Brand Name
abiraterone	Yonsa
abiraterone	Zytiga
abiraterone/niraparib	Akeega
apalutamide	Erleada
darolutamide	Nubeqa
enzalutamide	Xtandi
nilutamide	Nilandron